Form 4: Recursion Pharmaceuticals' President and COO, Tina Marriott, Executes Stock Transactions Under 10b5-1 Plan

Tina Marriott, President and COO of Recursion Pharmaceuticals, executed stock transactions involving the sale of 3,000 shares of Class A Common Stock at an average price of $8.775, and the exercise of stock options to acquire 3,000 shares at $1.06, according to a recent SEC Form 4 filing.

Summary

• Tina Marriott, the President and COO of Recursion Pharmaceuticals, filed a Form 4 with the SEC detailing changes in her beneficial ownership of the company's stock.
• On May 30, 2024, Marriott exercised stock options to acquire 3,000 shares of Class A Common Stock at a price of $1.06 per share.
• Simultaneously, she sold 3,000 shares of Class A Common Stock at a weighted average price of $8.775 per share, with individual sales ranging from $8.65 to $8.88.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on March 1, 2023.
• Following these transactions, Marriott directly owns 535,457 shares of Class A Common Stock.
• She also holds options to purchase a total of 1,643,949 additional shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-arranged plan. While the sale of shares could be perceived negatively, the existence of the 10b5-1 plan mitigates this concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Marriott still holds a significant number of shares and options, indicating continued alignment with the company's success.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it's part of a pre-planned strategy.

Risks

• Continued sales by Marriott could put downward pressure on the stock price.
• Investor sentiment could be negatively affected if similar sales occur frequently.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates ongoing transactions under a pre-arranged trading plan.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• Comparable companies like BioNTech, Moderna, and CRISPR Therapeutics also see regular Form 4 filings from their executives.
• The size and frequency of these transactions are generally in line with industry norms for executive compensation and diversification strategies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on their perception of insider selling.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates